The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...

Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world’s biggest drugmakers — Eli Lilly & Co. and Novo ...

The company is increasing its offerings to incorporate GLP-1 drugs such as Ozempic and Mounjaro – used to treat type 2 diabetes and, in some cases, obesity ... to Lilly’s weight loss ...

Experts say the growing use of weight loss drugs may be helping to reverse obesity trends. ABC News medical contributor Dr. John Brownstein breaks down the latest study. Eli Lilly says new ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Pharmaceutical company Eli Lilly ... obesity and diabetes. Besides the good news of minimal side effects and impressive results, though, the pill has an extremely unfortunate quality: its name ...

Just three days after the Pfizer news, Eli Lilly announced positive results from its Phase III trial of weight-loss drug ... with the drug being assessed for bot diabetes and obesity treatment.

May 7 (Reuters) - A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight loss ... of obesity drugs only while ...